Levi & Korsinsky notifies investors that it has commenced an investigation into ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) concerning potential violations of the federal securities laws.
On September 24, 2025, Acadia issued a press release "announcing top-line results from the Phase 3 COMPASS PWS trial evaluating the efficacy and safety of intranasal carbetocin (ACP-101) in patients with hyperphagia in Prader-Willi syndrome (PWS)." The press release disclosed that the drug "did not demonstrate a statistically significant improvement over placebo on the study's primary endpoint, change from baseline to Week 12 on the Hyperphagia Questionnaire for Clinical Trials (HQ-CT), nor was there separation from placebo on any secondary endpoint." Acadia's Head of Research and Development stated that, "given these results, we do not intend to investigate intranasal carbetocin any further." On this news, Acadia's stock price fell $2.34 per share, or 9.92%, to close at $21.26 per share on September 24, 2025.
If you suffered a loss on your ACADIA securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure





